NFX.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:44):
Our systems believe the stock currently is undervalued by 0.19% compare to its pairs and should correct upwards.

Stats
今日成交量	546 087
平均成交量	2.30M
市值	1.32M
EPS	£-0.000300 ( Q4 \| 2024-03-31 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	0 (Sector) 0 (Industry) 0
ATR14	£0 (0.00%)

AMYT.L -11.73%

APH.L -0.13%

AVCT.L 0.54%

AZN.L -0.44%

BMK.L 7.59%

BVXP.L -2.16%

C4XD.L 27.32%

CIR.L 0.00%

CLIN.L 0.11%

DEST.L -2.51%

DPH.L 0.05%

EAH.L 3.40%

ERGO.L 0.15%

ETX.L -6.74%

EVG.L 2.25%

FAB.L -1.59%

FARN.L -5.98%

FUM.L 0.27%

GDR.L 1.10%

GNS.L 1.45%

GSK.L -0.52%

HCM.L -0.36%

HEMO.L -2.66%

HIK.L -0.53%

IMM.L -1.15%

INDV.L 0.00%

IXI.L -5.25%

MTPH.L 1 794.74%

MXCT.L -2.17%

N4P.L -4.71%

NCYT.L -2.42%

NFX.L -5.00%

OBD.L 3.33%

OKYO.L -24.32%

ONC.L 0.45%

OPTI.L -3.63%

OVB.L -2.22%

OXB.L 2.58%

PRM.L -4.82%

PRTC.L 0.98%

PYC.L -6.25%

REDX.L 31.58%

RENE.L -2.17%

SAR.L 8.67%

SCLP.L -1.86%

SLN.L -0.93%

SNG.L 3.48%

STX.L 2.70%

TILS.L 8.33%

TRX.L -1.15%

VAL.L 0.00%

VEC.L 0.00%

相关性 (AI algo v.1.1b): Undervalued: 0.19% £0.162 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

Nuformix PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nuformix PLC 财务报表

Annual	2023
营收:	£0
毛利润:	£-36 749.00 (0.00 %)
EPS:	£-0.000800

FY	2023
营收:	£0
毛利润:	£-36 749.00 (0.00 %)
EPS:	£-0.000800

FY	2022
营收:	£0
毛利润:	£0 (0.00 %)
EPS:	£-0.00130

FY	2022
营收:	£50 000.00
毛利润:	£48 305.00 (96.61 %)
EPS:	£-0.00190

Financial Reports:

No articles found.

Nuformix PLC Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nuformix PLC

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.